Inside Precision Medicine March 27, 2024
Continuing a trend, yesterday AbbVie announced it will acquire Landos, a clinical-stage biotech focused on the development of novel, oral therapeutics for patients with autoimmune diseases. Landos’ lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family) with a bimodal mechanism of action (MOA), which is anti-inflammatory and facilitates epithelial repair.
Autoimmune diseases affect approximately one in ten individuals. The market for this category of diseases is expected to reach $185B over the next five years.
Last week, Mirador Therapeutics launched with more than $400 million to “revolutionize precision medicine for immune-mediated inflammatory and fibrotic diseases,” according to their release. They aim to do this by leveraging their proprietary Mirador360—a repository of immune-mediated...
Today's Sponsors
Today's Sponsor